SEC Tracker
Get the app
AFIB · As filed with the SEC

Acutus Medical cash flow statement, by quarter

The statement as Acutus Medical presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.

Consolidated Statements of Cash Flows · USD thousands

USD thousandsQ4 2024†
3 months ended Dec 31, 2024		Q3 2024†
3 months ended Sep 30, 2024		Q2 2024†
3 months ended Jun 30, 2024		Q1 2024
3 months ended Mar 31, 2024		Q4 2023†
3 months ended Dec 31, 2023		Q3 2023†
3 months ended Sep 30, 2023		Q2 2023†
3 months ended Jun 30, 2023		Q1 2023
3 months ended Mar 31, 2023
Cash flows from operating activities
Net loss(1,406)†(5,607)†(914)†(1,620)(33,765)†(13,237)†(18,346)†(16,315)
Less: Loss on discontinued operations95†4,799†552†(435)31,722†11,874†14,111†—
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense62†73†76†86(193)†3,267†2,380†1,297
AcQMap Systems converted to sales————(238)†0†——
Sales-type lease gain————310†0†——
Amortization of intangible assets————(150)†50†50†50
Non-cash stock-based compensation expense0†128†129†2021,760†3,893†3,053†1,904
Accretion of discounts on marketable securities, net0†0†(5)†(23)(110)†(281)†(510)†(527)
Amortization of debt issuance costs471†168†205†87246†113†108†104
Amortization of operating lease right-of-use assets188†184†180†178170†174†175†164
Loss on debt extinguishment————0†0†——
Goodwill impairment————0†0†0†0
Gain on sale of business, net(2,718)†(2,435)†(2,869)†(2,792)(3,153)†(2,648)†(2,072)†(1,207)
Direct costs paid related to sale of business————0†0†——
Change in fair value of warrant liability(108)†174†(564)†283(1,459)†(636)†604†(1,446)
Loss on disposal of property and equipment————(268)†(247)†239†38
Change in fair value of contingent consideration0†0†0†00†0†(77)†200
Changes in operating assets and liabilities:
Accounts receivable(549)†(1,177)†(1,503)†(819)(4,321)†2,290†225†(11)
Inventory2,401†1,022†675†(1,610)(14,051)†(927)†(2,110)†(1,611)
Employer retention credit receivable0†0†0†00†0†2,562†2,141
Prepaid expenses and other current assets(238)†104†65†117(1,354)†294†(281)†391
Other assets———0(495)†43†452†75
Accounts payable(435)†28†(1,482)†4043,308†208†663†873
Accrued liabilities1,196†11†(562)†(891)7,343†(801)†(830)†(2,433)
Operating lease liabilities———(117)(208)†24†(76)†(201)
Operating lease liabilities(234)†(228)†——(208)†24†——
Other long-term liabilities0†0†0†0(32)†12†9†(1)
Net cash used in operating activities - continuing operations(1,275)†(2,756)†(6,204)†(6,950)(14,097)†5,277†(5,734)†—
Net cash used in operating activities - discontinued operations(2,783)†(942)†(771)†(9,979)(3,916)†(19,285)†(9,635)†—
Net cash used in operating activities(4,058)†(3,698)†(6,975)†(16,929)(18,013)†(14,008)†(15,369)†(16,515)
Cash flows from investing activities
Proceeds from sale of business5,437†2,959†2,976†7,3000†0†0†17,000
Purchases of available-for-sale marketable securities0†0†0†0(1,244)†(4,641)†(5,861)†(28,019)
Sales of available-for-sale marketable securities0†0†——750†0†0†0
Maturities of available-for-sale marketable securities0†0†1,000†1,75011,750†22,000†21,750†26,500
Purchases of property and equipment36†(5)†(38)†(105)968†(617)†(959)†(232)
Net cash provided by investing activities - continuing operations5,473†2,954†4,438†8,94512,224†16,949†15,137†—
Net cash provided by (used in) investing activities - discontinued operations0†23†31†285(1,004)†0†0†—
Net cash provided by investing activities5,473†2,977†4,469†9,23011,220†16,949†15,137†15,249
Cash flows from financing activities
Repayment of debt0†0†——0†0†——
Penalty fees paid for early prepayment of debt————0†0†——
Borrowing under new debt, net of fees————0†0†——
Payment of debt issuance costs————(490)†0†——
Proceeds from the exercise of stock options0†0†0†00†0†0†4
Repurchase of common shares to pay employee withholding taxes—0†——35†(252)†(46)†(217)
Proceeds from employee stock purchase plan0†0†——0†0†25†0
Payment of contingent consideration0†———0†(1,923)†0†0
Net cash used in financing activities - continuing operations(225)†0†(2,625)†0(455)†(1,935)†2†—
Net cash used in financing activities - discontinued operations0†0†1†(42)(40)†0†(23)†—
Net cash used in financing activities(225)†0†(2,624)†(42)(495)†(1,935)†(21)†(213)
Effect of exchange rate changes on cash, cash equivalents and restricted cash234†(11)†(2)†02,373†52†433†8
Net change in cash, cash equivalents and restricted cash1,424†(732)†(5,132)†(7,741)(4,915)†1,058†180†(1,471)
Cash, cash equivalents and restricted cash, at the beginning of the period12,59513,32718,45926,20031,11530,05729,87731,348
Cash, cash equivalents and restricted cash, at the end of the period14,01912,59513,32718,45926,20031,11530,05729,877
Supplemental disclosure of cash flow information:
Cash paid for interest1,150†833†1,294†1,2671,281†1,273†1,251†1,207
Supplemental disclosure of noncash investing and financing activities:
Accounts receivable from sale of business(2,640)†10,314†(10,740)†4,9043,249†2,730†2,137†1,244
Change in unrealized (gain) loss on marketable securities0†0†70†(70)0†(3)†8†(12)
Change in unpaid purchases of property and equipment—0†0†0(35)†89†(29)†(25)
Contingent consideration escrow release————0†0†0†0
Net book value on AcQMap system sales-type leases————(238)†0†——
Amount of debt proceeds allocated to warrant liability————0†0†——

† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.

As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.